02:15 , Dec 16, 2017 |  BioCentury  |  Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
16:38 , Dec 15, 2017 |  BC Week In Review  |  Financial News

argenx raises $231M in follow-on

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $231 million through the sale of 4.4 million ADSs at $52 in a bumped-up follow-on underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. The price is...
03:48 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

argenx reports Phase I/II cancer data of CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) reported data from two Phase I/II trials of ARGX-110 at the American Society of Hematology (ASH) meeting in Atlanta. Preliminary data from six evaluable patients with newly diagnosed acute myelogenous leukemia...
21:12 , Dec 14, 2017 |  BC Extra  |  Financial News

argenx, Proteostasis, Dicerna raise follow-ons

Antibody company argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), respiratory company Proteostasis Therapeutics Inc. (NASDAQ:PTI) and RNA therapeutics play Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) raised a combined $311 million in follow-on offerings. argenx raised $231 million through the sale...
01:11 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; renal cancer Cell culture and mouse studies suggest SIRPA inhibitors could help treat Burkitt's lymphoma and renal cell carcinoma (RCC). In a CD20-positive Burkitt's lymphoma cell line co-cultured with human macrophages, an anti-SIRPA...
00:25 , Dec 12, 2017 |  BC Extra  |  Clinical News

argenx rises on ARGX-113, ARGX-110 readout

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) jumped $24.02 (79%) to $54.47 on NASDAQ Monday after reporting data on its two lead compounds, efgartigimod (ARGX-113) and ARGX-110. The biotech gained €14.20 (56%) to €39.40 on Euronext. Of 24...
23:13 , Nov 21, 2017 |  BC Extra  |  Preclinical News

Researchers develop mAb that enhances phagocytosis of tumor cells

In a paper published in...
19:51 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

argenx starts Phase II for anti-CD70 mAb ARGX-110

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) began the Phase II portion of an open-label, European Phase I/II trial evaluating IV ARGX-110 every 3 weeks to treat advanced malignancies expressing CD70 (CD27L) in about 54 patients. The company...
21:50 , May 18, 2017 |  BC Extra  |  Financial News

argenx climbs after raising $100M in NASDAQ listing

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) gained $6 (35%) to $23 in its first day of U.S. trading Thursday after it raised $100 million through the sale of 5.9 million ADSs at $17 in a NASDAQ offering...
22:10 , Apr 24, 2017 |  BC Extra  |  Financial News

argenx planning NASDAQ listing

Antibody engineering company argenx N.V. (Euronext:ARGX) filed to raise up to $74.8 million in a public offering of ADSs on NASDAQ underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow. argenx's lead candidate, ARGX-113...